Detalles de la búsqueda
1.
Effects of Interleukin-1ß Inhibition on Incident Anemia: Exploratory Analyses From a Randomized Trial.
Ann Intern Med
; 172(8): 523-532, 2020 04 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-32203978
2.
Effects of Interleukin-1ß Inhibition on Incident Hip and Knee Replacement : Exploratory Analyses From a Randomized, Double-Blind, Placebo-Controlled Trial.
Ann Intern Med
; 173(7): 509-515, 2020 10 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-32744862
3.
Residual inflammatory risk associated with interleukin-18 and interleukin-6 after successful interleukin-1ß inhibition with canakinumab: further rationale for the development of targeted anti-cytokine therapies for the treatment of atherothrombosis.
Eur Heart J
; 41(23): 2153-2163, 2020 06 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-31504417
4.
Anti-Inflammatory Therapy With Canakinumab for the Prevention of Hospitalization for Heart Failure.
Circulation
; 139(10): 1289-1299, 2019 03 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-30586730
5.
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.
N Engl J Med
; 377(12): 1119-1131, 2017 09 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-28845751
6.
Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial.
Lancet
; 391(10118): 319-328, 2018 01 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-29146124
7.
Relationship of Interleukin-1ß Blockade With Incident Gout and Serum Uric Acid Levels: Exploratory Analysis of a Randomized Controlled Trial.
Ann Intern Med
; 169(8): 535-542, 2018 10 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-30242335
8.
Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS).
Eur Heart J
; 39(38): 3499-3507, 2018 10 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-30165610
9.
Effect of interleukin-1ß inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial.
Lancet
; 390(10105): 1833-1842, 2017 Oct 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-28855077
10.
Safety and tolerability of canakinumab, an IL-1ß inhibitor, in type 2 diabetes mellitus patients: a pooled analysis of three randomised double-blind studies.
Cardiovasc Diabetol
; 13: 94, 2014 May 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-24884602
11.
Effects of interleukin-1ß inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial.
Circulation
; 126(23): 2739-48, 2012 Dec 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-23129601
12.
Lipoprotein(a) levels in a global population with established atherosclerotic cardiovascular disease.
Open Heart
; 9(2)2022 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-36252994
13.
Interleukin-1ß inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS).
Am Heart J
; 162(4): 597-605, 2011 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-21982649
14.
Inhibition of Interleukin-1ß and Reduction in Atherothrombotic Cardiovascular Events in the CANTOS Trial.
J Am Coll Cardiol
; 76(14): 1660-1670, 2020 10 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33004131
15.
Effects of Interleukin-1ß Inhibition on Blood Pressure, Incident Hypertension, and Residual Inflammatory Risk: A Secondary Analysis of CANTOS.
Hypertension
; 75(2): 477-482, 2020 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-31884854
16.
Inhibition of CETP by torcetrapib attenuates the atherogenicity of postprandial TG-rich lipoproteins in type IIB hyperlipidemia.
Arterioscler Thromb Vasc Biol
; 28(1): 148-54, 2008 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-17951324
17.
Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes.
J Am Coll Cardiol
; 71(21): 2392-2401, 2018 05 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-29544870
18.
Inhibition of Interleukin-1ß by Canakinumab and Cardiovascular Outcomes in Patients With Chronic Kidney Disease.
J Am Coll Cardiol
; 71(21): 2405-2414, 2018 05 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-29793629
19.
New strategies for the development of lipid-lowering therapies to reduce cardiovascular risk.
Eur Heart J Cardiovasc Pharmacother
; 4(2): 119-127, 2018 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29194462
20.
Pharmacokinetic and pharmacodynamic characteristics of single-dose Canakinumab in patients with type 2 diabetes mellitus.
Clin Ther
; 36(11): 1625-37, 2014 Nov 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-25240532
Resultados
1 -
20
de 20
1
Próxima >
>>